About Us
- Viking Global Foundation
Our Team
Investments
Careers
Contact Us
Investor Login

Diagonal Therapeutics

by Pat Scanlan | May 1, 2024 | Active

Preclinical-stage biotech company developing novel agonist antibodies

Search

Recent Posts

Recent Comments

No comments to show.

We invest globally with a long-term, fundamental, research-based perspective. Driven by the pursuit of excellence, we strive to deliver operational excellence and the highest risk-adjusted returns.

Navigation

About Us
- Viking Global Foundation
Our Team
Investments
Careers
Contact Us
Investor Login

Offices

Stamford
Hong Kong
London
New York
San Francisco

Contact

General inquiries: [email protected]

Recruiting inquiries: [email protected]

Please be aware that Viking’s name, brand, and reputation may be misused by unauthorized third parties. We do not provide investment advice or otherwise solicit capital via social media, including LinkedIn and Facebook, or encrypted chat platforms, including Telegram, WhatsApp, or Signal. If you receive a communication that appears suspicious, please report it to us at [email protected].

© 2025 Viking Global Investors LP. Use of this website is governed by the User Agreement. The content contained on this site is provided to users ‘as is’ without any express or implied warranty.

User Agreement | Privacy Notice | European Engagement Policy | FinSA Disclosures | Transparency in Health Coverage | MSA Transparency Statement

Skip to main content